Here, we determine the antineoplastic effect of the T22-PE24-H6 nanoparticle actively targeting CXCR4+ DLBCL cells to evaluate whether it could increase the therapeutic window of immunotoxins. The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.